Source: CTV News
Market Herald logo


Be the first with the news that moves the market

Today’s stocks plunged for Ottawa-based company Shopify (SHOP) after it released its latest quarterly revenue results.

Although the company’s total revenues increased by 26 per cent during its fourth quarter, its total operating loss was reported to be 10 per cent higher than the same time last year.

Revenues increase but not as expected

The company’s adjusted operating income was $61.0 million, about 4.00 per cent of its revenue. The difference is said to be caused by increases in compensation driven by the application of a new compensation system and increased headcount. The fourth quarter adjusted operating income excluded a real estate-related impairment charge.

These numbers pale in comparison of the rapid growth the company saw at the beginning of the pandemic when sales rose to about 86 per cent. Shopify stated it has taken this into consideration for its progress and assumed that its numbers would cool off.

Despite all this, the company anticipates seeing revenue growth in the “high-teen percentages” compared to year-over-year moving forward through this year.

New financial outlook calls for price increases

Shopify’s financial outlook for 2023 also included changing the price of its subscription plans, the expected impact of Shopify Fulfillment Network and Deliverr, and increased personnel-related expenses.

However, Shopify’s stocks on the TSX took a hard dip after hours after yesterday’s market and closed today’s market with a loss of 11.05 points.

Last summer, Shopify axed roughly 1,000 jobs which were one of the first tech companies to begin the job layoff wave that still echoes in the industry today.

Shopify (SHOP) closed today’s market at $60.39 per share, down 15.47 per cent.

More From The Market Herald
The Market Herald Video

" Datametrex (TSXV:DM) details exciting initiatives ahead

Datametrex (DM) has issued a corporate update as of March 2023.

" Innocan Pharma (CSE:INNO) reports successful efficacy test for vaginal derma product

Innocan Pharma (INNO) has announced successful results from a controlled efficacy test of its vaginal derma product.

" @ the Bell: TSX bounces back again

Euro banking drama had a ripple effect felt on Bay Street Friday but Canada’s main stock index dodged another close in the red.

" Survey shows fraud risk a rising concern for Canadians

Latest survey by Royal Bank of Canada shows Canadians are concerned about spotting scams and that fraud risk will get worse if a recession